Last reviewed · How we verify
Lecanemab IV
Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.
Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain. Used for Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage with confirmed amyloid pathology).
At a glance
| Generic name | Lecanemab IV |
|---|---|
| Also known as | BAN2401 |
| Sponsor | Eisai Inc. |
| Drug class | Monoclonal antibody (anti-amyloid-beta) |
| Target | Amyloid-beta protofibrils |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Lecanemab selectively targets protofibrils, which are intermediate aggregates of amyloid-beta believed to be particularly neurotoxic in Alzheimer's disease. By binding to these protofibrils, the antibody facilitates their removal through microglial phagocytosis and peripheral clearance, thereby reducing amyloid burden in the brain and slowing cognitive decline in early symptomatic disease.
Approved indications
- Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage with confirmed amyloid pathology)
Common side effects
- Amyloid-related imaging abnormalities with edema (ARIA-E)
- Amyloid-related imaging abnormalities with microhemorrhages (ARIA-H)
- Infusion reactions
- Headache
- Flu-like illness
Key clinical trials
- AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (PHASE3)
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease (PHASE3)
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease (PHASE2)
- A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (PHASE3)
- A Study of Subcutaneous Lecanemab in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lecanemab IV CI brief — competitive landscape report
- Lecanemab IV updates RSS · CI watch RSS
- Eisai Inc. portfolio CI